Literature DB >> 9455978

The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis.

S J McCann1, S M Pond, K M James, D G Le Couteur.   

Abstract

We performed a case-control study to investigate the association of the poor metaboliser genotype of the cytochrome P450 2D6 gene with Parkinson's disease (PD). Genotyping was determined by the polymerase chain reaction followed by digestion with restriction enzymes. The poor metaboliser genotype was more frequent in 112 patients with PD than in 206 matched controls (odds ratio 1.7, 95% CI: 0.94-2.45). A meta-analysis of these results together with ten other published studies gave a pooled odds ratio for the poor metaboliser genotype of 1.47 (95% CI: 1.18-1.96, P=0.01). Thus, the poor metaboliser genotype has a small but highly significant association with PD which would be easily missed in small studies. Research now should focus on the mechanism of this association.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9455978     DOI: 10.1016/s0022-510x(97)00179-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  21 in total

Review 1.  Prospects of genetic epidemiology in the 21st century.

Authors:  Marieke C J Dekker; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

3.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

4.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

Review 5.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

6.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

Authors:  Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

8.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

9.  Characterization and localization of cytochrome P450 mediated metabolism of MPTP to nor-MPTP in mouse brain: relevance to Parkinson's disease.

Authors:  S C Upadhya; M R Boyd; V Ravindranath
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

10.  Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.

Authors:  Cole Tolledo; Marlaina R Stocco; Sharon Miksys; Frank J Gonzalez; Rachel F Tyndale
Journal:  Mol Neurobiol       Date:  2020-03-18       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.